Dentons advises CDP Venture Capital on funding for Rubedo Life Science

The law firm Dentons advised CDP Venture Capital in closing a Series A funding round for Rubedo Life Sciences, a California-based biopharmaceutical company focused on developing innovative therapies for cellular aging.

Dentons advises CDP Venture Capital on funding for Rubedo Life Sciences

This investment will support Rubedo in establishing its European headquarters in Milan, where it plans to initiate its first-in-human study of RLS-1496, a treatment for inflammatory skin diseases, in 2025. This will be Rubedo's first clinical study conducted outside its California base. The Dentons team was led by partner Antonio Legrottaglie, with associate Manuel Sturba and trainee Bianca Balestri. CDP Venture Capital was represented by its in-house legal team, led by attorneys Alessandro Di Gioia and Debora Perciballi.